Literature DB >> 8856617

A functional index in myositis.

A Josefson1, E Romanus, J Carlsson.   

Abstract

OBJECTIVE: To evaluate the interrater reliability and the construct validity of a specially constructed functional index and to assess functional status in 23 patients with myositis; and to describe the occurrence, intensity, and distribution of pain in these patients.
METHODS: The functional test scored muscle endurance in extremities, neck, and trunk, grip strength, peak expiratory flow, turning in bed, and transferring from lying in bed to sitting. The scores of the different functions were added to create a functional index. The patients' subjective gradings of disability and pain intensity were indicated on a category scale. Blood samples for analyses of muscle enzyme levels were obtained in connection with the functional tests.
RESULTS: The interrater reliability of the functional index was high. Grip strength and muscle endurance in shoulder abduction and flexion, hip flexion, and a step test and heel and toe lifting were significantly reduced compared to controls. Peak expiratory flow was lowered in 4 patients. The functional index did not correlate significantly with the laboratory tests, but there was significant correlation between the weakness of the lower extremities and the subjective grading of disability. All patients but one had experienced severe pain during the course of the disease.
CONCLUSION: The described functional index has high interrater reliability, but its construct validity and sensitivity as a monitor of response to medication and training need further confirmation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8856617

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  14 in total

1.  Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.

Authors:  Sevim Barbasso Helmers; Maryam Dastmalchi; Helene Alexanderson; Inger Nennesmo; Mona Esbjörnsson; Björn Lindvall; Ingrid E Lundberg
Journal:  Ann Rheum Dis       Date:  2007-02-02       Impact factor: 19.103

2.  Signs of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis.

Authors:  C Dorph; P Englund; I Nennesmo; I E Lundberg
Journal:  Ann Rheum Dis       Date:  2006-07-10       Impact factor: 19.103

Review 3.  Exercise: an important component of treatment in the idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 4.  Outcomes and disease activity measures for assessing treatments in the idiopathic inflammatory myopathies.

Authors:  Chester V Oddis
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 5.  Creatine for treating muscle disorders.

Authors:  Rudolf A Kley; Mark A Tarnopolsky; Matthias Vorgerd
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 6.  Patient-reported outcomes and adult patients' disease experience in the idiopathic inflammatory myopathies. report from the OMERACT 11 Myositis Special Interest Group.

Authors:  Helene Alexanderson; Maria Del Grande; Clifton O Bingham; Ana-Maria Orbai; Catherine Sarver; Katherine Clegg-Smith; Ingrid E Lundberg; Yeong Wook Song; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2014-01-15       Impact factor: 4.666

Review 7.  The assessment and importance of disease activity versus disease damage in patients with inflammatory myopathy.

Authors:  Shabina M Sultan
Journal:  Curr Rheumatol Rep       Date:  2003-12       Impact factor: 4.592

Review 8.  Inflammatory muscle disease: clinical presentation and assessment of patients.

Authors:  Helene Alexanderson; Ingrid E Lundberg
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 9.  Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI).

Authors:  Lisa G Rider; Victoria P Werth; Adam M Huber; Helene Alexanderson; Anand Prahalad Rao; Nicolino Ruperto; Laura Herbelin; Richard Barohn; David Isenberg; Frederick W Miller
Journal:  Arthritis Care Res (Hoboken)       Date:  2011-11       Impact factor: 4.794

10.  Functional Index-3: A Valid and Reliable Functional Outcome Assessment Measure in Patients With Dermatomyositis and Polymyositis.

Authors:  Floranne C Ernste; Christopher Chong; Cynthia S Crowson; Tanaz A Kermani; Orla Ni Mhuircheartaigh; Helene Alexanderson
Journal:  J Rheumatol       Date:  2020-04-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.